Welcome to our dedicated page for ZIMVIE news (Ticker: ZIMV), a resource for investors and traders seeking the latest updates and insights on ZIMVIE stock.
ZimVie Inc (ZIMV) delivers innovative dental and spine solutions through advanced biomaterials and digital workflow integration. This news hub provides investors and medical professionals with centralized access to official updates spanning product developments, financial disclosures, and strategic initiatives.
Track announcements across ZimVie's core segments: dental innovations like implant surface technologies and CAD/CAM restorative systems, plus spine surgery advancements in fusion devices and surgical instrumentation. Receive timely updates on regulatory milestones, partnership agreements, and clinical research outcomes.
Our curated news collection enables efficient monitoring of ZimVie's progress in merging digital planning tools with medical device engineering. Discover updates on RealGUIDE® software enhancements, biomaterial research breakthroughs, and market expansion strategies while maintaining compliance with financial disclosure standards.
Bookmark this page for structured access to ZimVie's evolving position in life sciences. Combine technical insights with corporate updates to inform your analysis of this dual-segment medical technology innovator.
ZimVie (Nasdaq: ZIMV), a global dental implant market leader, has reported its Q2 2025 financial results and announced a definitive agreement to be acquired by ARCHIMED for $19.00 per share in cash. The company recorded net sales of $116.7 million from continuing operations, showing a slight decrease of 0.1% on a reported basis and 2.1% in constant currency compared to Q2 2024.
The company reported a net loss of $3.8 million, improving from a $9.6 million loss in Q2 2024, with the net loss margin improving to 3.3%. Adjusted EBITDA reached $17.5 million, representing a 15.0% margin, an increase of $1.6 million from the previous year. Upon completion of the ARCHIMED acquisition, expected by year-end 2025, ZimVie will become private and delist from NASDAQ.
ZimVie (Nasdaq: ZIMV), a global dental implant market leader, has announced its Q2 2025 financial results will be released on July 30, 2025 after market close. This follows the company's recent announcement of a definitive agreement to be acquired by ARCHIMED for $19.00 per share in cash.
Due to the pending acquisition, which is expected to close by year-end 2025, ZimVie has cancelled its Q2 earnings call and withdrawn its fiscal 2025 guidance. Upon transaction completion, ZimVie will become private and delist from NASDAQ. The deal requires stockholder approval and regulatory clearances.
ZimVie (Nasdaq: ZIMV) has entered into an exclusive distribution agreement with Osstem Implant to expand its dental implant presence in China. The strategic partnership leverages Osstem's market-leading position and extensive distribution network spanning over 90 Chinese cities.
Osstem Implant, established in China since 2006, conducts nearly 500 clinical training sessions annually and will have exclusive commercial rights to distribute ZimVie implant systems in the Chinese market, which has an estimated demand of over 10 million units annually.
ZimVie (Nasdaq: ZIMV), a global dental implant market leader, has announced a definitive agreement to be acquired by healthcare-focused investment firm ARCHIMED in an all-cash transaction valued at approximately $730 million.
Under the agreement, ZIMV shareholders will receive $19.00 per share in cash, representing a 99% premium to the company's 90-day volume-weighted average price of $9.57. The transaction, unanimously approved by ZimVie's Board of Directors, is expected to close by year-end 2025, subject to stockholder and regulatory approvals.
The company has initiated a 40-day go-shop period through August 29, 2025, during which it may solicit alternative proposals. Upon completion, ZimVie will become private and delist from NASDAQ.
ZimVie (Nasdaq: ZIMV), a global life sciences leader specializing in the dental market, has announced its participation in the upcoming Stifel 2025 Jaws & Paws Conference. The company's management will deliver a presentation on Wednesday, May 28, 2025, at 3:00 p.m. Eastern Time. Investors and interested parties can access both the live webcast and archived recording of the presentation through ZimVie's investor website at investor.zimvie.com.
ZimVie (NASDAQ: ZIMV), a global dental life sciences company, reported its Q1 2025 financial results. The company posted net sales of $112.0 million, representing a decline of 5.2% (4.1% in constant currency) compared to Q1 2024. The company reported a net loss of $2.6 million, an improvement from the $11.5 million loss in Q1 2024, with net loss margin improving by 740 basis points to (2.3)%.
Adjusted EBITDA reached $17.6 million (15.7% margin), increasing by $5.1 million from Q1 2024. The company's adjusted diluted EPS was $0.27. For full-year 2025, ZimVie projects net sales between $445M-$460M, adjusted EBITDA of $65M-$70M, and adjusted EPS of $0.80-$0.95.
ZimVie (Nasdaq: ZIMV), a global life sciences leader in the dental market, has announced its plans to release first quarter 2025 financial results after market close on May 8, 2025. The company will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results. Interested participants are advised to register online for the call, preferably more than 15 minutes before it begins. A webcast replay will be made available on investor.zimvie.com.
ZimVie Inc. (Nasdaq: ZIMV) has launched its new Immediate Molar Implant System in the United States, expanding its TSX® and T3 PRO® Implant systems portfolio. The innovative system addresses the challenges of replacing extracted molars with implants, offering enhanced precision and control during molar extraction procedures.
The system features specially engineered instrumentation and optimized wide-diameter implants that provide improved primary stability. Its proprietary DAE coronal surface technology potentially reduces peri-implantitis risk by up to 20%. Notably, the system cuts traditional treatment time in half and maintains restorative compatibility with ZimVie's existing implant systems, minimizing switching costs.
ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The company's management team will deliver a presentation on Tuesday, April 8, 2025 at 3:00 p.m. Eastern Time / 12:00 p.m. Pacific Time.
Investors and interested parties can access the live webcast and archived recording of the presentation through ZimVie's investor website at investor.zimvie.com.
FAQ
What is the current stock price of ZIMVIE (ZIMV)?
What is the market cap of ZIMVIE (ZIMV)?
